A prospective case-control study demonstrates that myocardial fibroblast activation persists in heart failure patients and follows distinct spatial patterns depending on etiology. Using [68Ga]FAPI-46 PET/MRI, researchers found that higher baseline uptake predicts worse outcomes, suggesting potential for risk stratification and targeted antifibrotic therapy development.